Journal of Urban Health

, Volume 82, Issue 3, pp 488–497 | Cite as

Access and utilization of HIV treatment and services among women sex workers in Vancouver’s downtown eastside

  • Kate Shannon
  • Vicki Bright
  • Janice Duddy
  • Mark W. Tyndall


Many HIV-infected women are not realizing the benefits of highly active antiretroviral therapy (HAART) despite significant advancements in treatment. Women in Vancouver’s Downtown Eastside (DTES) are highly marginalized and struggle with multiple morbidities, unstable housing, addiction, survival sex, and elevated risk of sexual and drug-related harms, including HIV infection. Although recent studies have identified the heightened risk of HIV infection among women engaged in sex work and injection drug use, the uptake of HIV care among this population has received little attention. The objectives of this study are to evaluate the needs of women engaged in survival sex work and to assess utilization and acceptance of HAART. During November 2003, a baseline needs assessment was conducted among 159 women through a low-threshold drop-in centre servicing street-level sex workers in Vancouver. Cross-sectional data were used to describe the sociodemographic characteristics, drug use patterns, HIV/hepatitis C virus (HCV) testing and status, and attitudes towards HAART. High rates of cocaine injection, heroin injection, and smokeable crack cocaine use reflect the vulnerable and chaotic nature of this population. Although preliminary findings suggest an overall high uptake of health and social services, there was limited attention to HIV care with only 9% of the women on HAART. Self-reported barriers to accessing treatment were largely attributed to misinformation and misconceptions about treatment. Given the acceptability of accessing HAART through community interventions and women specific services, this study highlights the potential to reach this highly marginalized group and provides valuable baseline information on a population that has remained largely outside consistent HIV care.


Antiretroviral therapy HIV/AIDS Injection drug use Women sex workers 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267–1274.CrossRefPubMedGoogle Scholar
  2. 2.
    Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitty JA, Flanigan T. Community-based interventions for marginalized populations. Clin Infect Dis. 2004;38:S373-S375.CrossRefPubMedGoogle Scholar
  4. 4.
    Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47–58.PubMedGoogle Scholar
  5. 5.
    Palepu A, Tyndall MW, Li K, et al. Adherence and sustainability of antiretroviral therapy among injection drug users in Vancouver. Can J of Infect Dis. 2001; 12(suppl B):32B.Google Scholar
  6. 6.
    Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–549.CrossRefPubMedGoogle Scholar
  7. 7.
    Strathdee SA, O’Driscoll PT, Galai N, et al. Trends in use of optimal, suboptimal, and no HIV antiretroviral therapy. Paper presented at: XV International AIDS Conference; July 11th, 2004; Bangkok, Thailand.Google Scholar
  8. 8.
    Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr. 2003 2004;32:452–461.PubMedGoogle Scholar
  9. 9.
    Wood E, Montaner JS, Tyndall MW, Schechter MT, O’Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003;188:1164–1170.CrossRefPubMedGoogle Scholar
  10. 10.
    Miller CL, Spittal PM, LaLiberte N, et al. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. JAIDS. 2002;30:1–10.Google Scholar
  11. 11.
    Spittal PM, Craib KJ, Wood E, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002;166:894–899.PubMedGoogle Scholar
  12. 12.
    Spittal PM, Bruneau J, Craib KJ, et al. Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. AIDS Care. 2003;15:187–195.CrossRefPubMedGoogle Scholar
  13. 13.
    Kral A, Bluthenthal R, Lorvick J, et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397–1401.CrossRefPubMedGoogle Scholar
  14. 14.
    Strathdee S, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80:iii7-iii14.PubMedGoogle Scholar
  15. 15.
    Astemborski J, Vlahov D, Warren D, et al. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health. 1994;84:382–387.PubMedGoogle Scholar
  16. 16.
    Gollub EL, Rey D, Obadia Y, Moatti JP. Gender differences in risk behaviours among HIV+ persons with an IDU history: the link between partner characteristics and women’s higher drug-sex risks. Sex Transm Dis. 1998;25:483–488.PubMedGoogle Scholar
  17. 17.
    Health Canada. HIV/AIDS among Aboriginal persons in Canada: A Continuing concern In: HIV/AIDS Epi Update. Ottawa: Bureau of HIV/AIDS, STD and TB; 2003:35–40.Google Scholar
  18. 18.
    Craib KJ, Spittal PM, Wood E, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003;168:19–31.PubMedGoogle Scholar
  19. 19.
    Needle RH, Trotter RT, Singer M, et al. Rapid assessment of the HIV/AIDS crisis in racial and ethnic minority communities: an approach for timely community interventions. Am J Public Health. 2003;93:970–979.PubMedCrossRefGoogle Scholar
  20. 20.
    Johnson BL, ven Haeften I, Fishbein M, Kasprzyk D, Montano D. Factors influencing IDU and non-IDU female commercial sex workers’ intentions to always use condoms for vaginal sex with their regular partners. Psychol Health Med. 2001;6:207–222.CrossRefGoogle Scholar
  21. 21.
    Booth R, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviours: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. 2000;58:219–226.CrossRefPubMedGoogle Scholar
  22. 22.
    Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics—crack cocaine use and HIV infection among inner-city young adults. N Engl J Med. 1994;331:1422–1427.CrossRefPubMedGoogle Scholar
  23. 23.
    Vidal-Trecan G, Coste J, Varescon-Pousson I, Christoforov B, Boissonnas A. HCV status knowledge and risk behaviours amongst intravenous drug users. Eur J Epidemiol. 2000;16:439–445.CrossRefPubMedGoogle Scholar
  24. 24.
    Palepu A, Strathdee SA, Hogg RS, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health. 1999;76:409–418.CrossRefPubMedGoogle Scholar
  25. 25.
    Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;14:47–58.CrossRefPubMedGoogle Scholar
  26. 26.
    Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. JAIDS. 2002;31:S123-S127.PubMedGoogle Scholar
  27. 27.
    Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–266.CrossRefPubMedGoogle Scholar
  28. 28.
    Kresina TF, Normand J, Khalsa J, Mitty J, Flanigan T, Francis H. Addressing the need of treatment paradigms for drug-abusing patients with multiple morbidities Clin Infect Dis. 2004;38:S398-S401.CrossRefPubMedGoogle Scholar
  29. 29.
    Macalino GE, Mitty J, Bazerman LB, Singh K, McKensie M, Flanigan T. Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clin Infect Dis. 2004;38(suppl 5):S393-S397.CrossRefPubMedGoogle Scholar
  30. 30.
    Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004;38:S376-S387.CrossRefPubMedGoogle Scholar
  31. 31.
    Pollack HA, Khoshnood K, Blankenship KM, Altice FL. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med. 2002;17:341–348.CrossRefPubMedGoogle Scholar
  32. 32.
    Aral SO, Mann JM. Commercial sex work and STD: the need for policy interventions to change societal patterns. Sex Transm Dis. 1998;25:455–456.PubMedGoogle Scholar
  33. 33.
    Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons learned from the Vancouver injecting drug user study. AIDS. 1997;11:F59-F65.CrossRefPubMedGoogle Scholar
  34. 34.
    De Irala J, Bigelow C, Mccusker J, Hindin R, Zheng L. Rehability of self-reported human immunodeficiency virus risk behaviours in a residential drug treatment population. J Epidemiol. 1996;143:725–732.Google Scholar

Copyright information

© Oxford University Press on behalf of the New York Academy of Medicine 2005

Authors and Affiliations

  • Kate Shannon
    • 1
  • Vicki Bright
    • 2
  • Janice Duddy
    • 2
  • Mark W. Tyndall
    • 1
    • 3
  1. 1.British Columbia Centre for Excellence in HIV/AIDSSt. Paul’s HospitalVancouverCanada
  2. 2.Women’s Information and Safe House (WISH) Drop-in Centre SocietyVancouverCanada
  3. 3.Department of MedicineUniversity of British ColumbiaVancouverCanada

Personalised recommendations